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Abstract
Plasma Plasmodium falciparum histidine-rich protein-2 (PfHRP-2) concentrations, a measure of parasite biomass, have been
correlated with malaria severity in adults, but not yet in children. We measured plasma PfHRP-2 in Tanzanian children with
uncomplicated (n = 61) and cerebral malaria (n = 45; 7 deaths). Median plasma PfHRP-2 concentrations were higher in
cerebral malaria (1008 [IQR 342–2572] ng/mL) than in uncomplicated malaria (465 [IQR 36–1426] ng/mL; p = 0.017). In
cerebral malaria, natural log plasma PfHRP-2 was associated with coma depth (r =20.42; p = 0.006) and mortality (OR: 3.0
[95% CI 1.03–8.76]; p = 0.04). In this relatively small cohort study in a mesoendemic transmission area of Africa, plasma
PfHRP-2 was associated with pediatric malaria severity and mortality. Further studies among children in areas of Africa with
higher malaria transmission and among children with different clinical manifestations of severe malaria will help determine
the wider utility of quantitative PfHRP-2 as a measure of parasite biomass and prognosis in sub-Saharan Africa.
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Introduction
Sequestration of parasitized red blood cells within the deep
organ microvasculature is thought to explain the pathogenicity of
Plasmodium falciparum, and results from the ability of parasitized
erythrocytes to cytoadhere to endothelial cells in post-capillary
venules [1]. Autopsies of cerebral malaria have demonstrated 26–
40 times the burden of Plasmodium falciparum parasites in the deep
tissue circulation of the brain compared to peripheral blood [2,3].
This phenomenon is thought to explain the poor association
between malaria severity and parasitemia measured by peripheral
blood microscopy [4].
Histidine-rich protein-2 (PfHRP-2) is a protein synthesized by P.
falciparum that facilitates heme polymerization to hemozoin [5].
The parasite releases PfHRP-2 as a water-soluble protein into the
bloodstream of infected humans [5]. Quantitative PfHRP-2 has
been identified as a metric of the total parasite biomass, as it
includes antigen release from the sequestered parasite biomass,
which is not accurately discernible on peripheral blood smear [4].
Plasma PfHRP-2 levels at presentation correlated with severity of
malaria illness in adults from Thailand [4] and Indonesian Papua
[6]. In both these series, plasma PfHRP-2 was an independent
predictor of mortality [4,6]. However, this has not yet been shown
in African children. A recent study in Papua New Guinean
children found no association between plasma PfHRP-2 and
severity of malaria [7]. Some have proposed that differences in
age, PfHRP-2 strain variation, and/or intensity of transmission
may influence the utility of plasma PfHRP-2 in predicting parasite
biomass. In Africa, where transmission is generally higher than
Asia, persistent circulating plasma PfHRP-2 from recent infection
has been hypothesized to potentially overestimate parasite biomass
[7], given that blood PfHRP-2 can persist up to four weeks after
successful drug treatment [8]. With high rates of asymptomatic
parasitemia in Africa and Papua New Guinea, low plasma PfHRP-
2 levels in children clinically diagnosed with severe malaria may
suggest an alternative non-malarial cause of severe disease with
incidental parasitemia.
Although there is a clear association with disease severity in
Asia-Pacific adults, the greatest burden of severe malaria
morbidity and mortality is in African children [9]. To examine
the association between malaria severity and parasite biomass in
this population, we measured plasma PfHRP-2 levels in children
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with cerebral malaria and uncomplicated malaria in a mesoen-
demic transmission area of Tanzania [10]. We hypothesized that
plasma PfHRP-2 would be associated with disease severity and
death.
Methods
Study Design and Site
We conducted a prospective observational study in Dar Es
Salaam, Tanzania, a city (population ,3.2 million) with mesoen-
demic transmission of falciparum malaria [10]. Children with
uncomplicated or cerebral malaria were enrolled from the clinics
and the inpatient wards of Amana and Mwanayamala Districts
Hospitals and commenced antimalarial therapy. The distance
between these two district hospitals is 6.5 kilometers, and both are
located in central areas of Dar es Salaam. Once enrolled, children
with cerebral malaria were transferred to the clinical research unit
at the Hubert Kairuki Memorial University Hospital for further
evaluation and care. The sample sizes in both the uncomplicated
and cerebral malaria groups were comparable to those previously
found sufficient by Yeo et al to demonstrate a significant
relationship between plasma PfHRP-2 and both disease severity
and mortality in adults [6]. Approval for this study was obtained
from the institutional review boards of Hubert Kairuki Memorial
University, National Medical Research Institute, Tanzania,
University of Utah, Loyola University, and Duke University.
Informed consent was obtained from parents or guardians of all
children; human experimentation guidelines of the U.S. De-
partment of Health and Human Services were followed.
Patients and Sampling
Children were aged from 6 months to 6 years. Inclusion criteria
for cerebral malaria were defined by WHO: any level of P.
falciparum parasitemia on peripheral blood smear; unarousable
coma (Blantyre Coma Score #2) not attributable to hypoglycemia
(blood glucose level ,40 mg/dL) and persisting more than 60
minutes after any convulsion; no other identifiable cause of coma
[1]. Inclusion criteria for those with uncomplicated malaria were:
a clinical syndrome consistent with malaria and a documented
fever (temperature $38uC) or history of fever within 48 hours
from time of enrollment; P. falciparum parasitemia .10,000
parasites/mL on Giemsa-stained blood film and positive P.
falciparum rapid diagnostic test (Paracheck-Pf [Omega Diagnos-
tics]); and no other cause of fever identified.
Exclusion criteria for both groups with malaria were any of the
following: microscopic evidence of mixed infection with any other
Plasmodium species; bacterial co-infection as evidenced by a positive
blood, urine or cerebrospinal fluid (CSF) culture; CSF analysis
indicative of bacterial meningitis; quinine or artemesinin combi-
nation therapy initiated .18 hours prior to enrollment; and/or
hemoglobin ,5 mg/dL. Erythrocyte transfusions were not readily
available at our study sites. Children were also excluded from
enrollment as uncomplicated malaria if they exhibited WHO
warning signs suggestive of severe disease: inability to suckle, eat
and/or drink; excessive vomiting; abnormal respiratory rate or
respiratory distress as evidenced by accessory muscle use,
suprasternal retractions, or intercostal retractions; recent history
of convulsions; altered mental status; or inability to sit unaided.
Clinical Evaluation and Management
At presentation, demographic information, clinical history, and
examination were documented using standardized case report
forms. Capillary blood samples were obtained for Giemsa-stained
thick and thin blood smears as well as on-site rapid diagnostic
testing (Paracheck-Pf [Omega Diagnostics]). Venous samples for
routine laboratory analysis included complete blood count (Beck-
man-Coulter, Model Act 10), sodium, potassium, chloride,
bicarbonate, blood urea nitrogen, creatinine, and venous blood
gas (i-STATH 1 [Abbott Laboratories]). Blood cultures were
obtained in all children with uncomplicated and cerebral malaria
to rule out concomitant bacteremia. Lumbar puncture with
opening pressure was performed in all patients with coma to
evaluate for meningitis. Cerebrospinal fluid analysis included the
following: glucose and protein levels; cell count with differential by
trained microscopists; and bacterial culture.
Plasma PfHRP-2 was measured by ELISA as previously
described [6] using primary and secondary monoclonal antibodies
to P. falciparum HRP-2 (MPFM-55A and MPFG-55P, Immunology
Consultant Laboratories). Concentrations were derived from
standard curves utilizing purified PfHRP-2 kindly provided by D
Sullivan (Johns Hopkins School of Public Health). Samples with
ODs outside the linear part of the curve were repeated at an
appropriate dilution until an accurate concentration was de-
termined. The lower limit of detection was 1.5 ng/mL.
Children with uncomplicated malaria and cerebral malaria
received anti-malarial therapy and other supportive care as per
standard Tanzanian national protocols (artemesinin combined
therapy and IV quinine, respectively). Treatment was initiated as
soon as the diagnosis of malaria was suspected. Children with
cerebral malaria were re-examined daily until death or hospital
discharge.
Statistical Methods
Statistical analysis was performed using SAS (version 9.2).
Results are presented as mean with 95% confidence intervals for
normally distributed continuous variables or median with
interquartile range for variables with non-parametric distribution.
Non-parametric tests and natural log transformation of variables
were used when the assumption of normality was violated.
Differences between PfHRP-2 values in uncomplicated malaria
and cerebral malaria cases were compared using Wilcoxon rank-
sum scores two-sample test. Further comparisons of PfHRP-2
values between uncomplicated malaria, cerebral malaria survi-
vors, and cerebral malaria fatal cases were performed using
a Kruskal-Wallis test as well as the Wilcoxon rank-sum tests with
the Holm’s Step Down Procedure for partitioning alpha.
Differences between normally distributed continuous variables
were compared using Student’s t-test. Correlation between
variables was evaluated using Spearman’s correlation coefficients.
In the cerebral malaria group, logistic regression was used to
determine the association between death and plasma PfHRP-2
concentrations and clinical variables previously shown to be
associated with mortality (coma score and plasma bicarbonate)
[11]. Goodness-of-fit was assessed by the Hosmer-Lemeshow test.
Results
We screened 227 febrile children for uncomplicated malaria
between November 2007 and January 2011. Of these, 67 were
consented, six were excluded because they did not meet inclusion/
exclusion criteria, leaving 61 enrolled participants (49 and 12 from
Amana and Mwanayamala District Hospitals, respectively). We
screened 153 febrile children with central nervous system
conditions (mostly stupor or coma) for cerebral malaria. Fifty-
one met inclusion criteria for cerebral malaria and were
consented. Of these, six were excluded, leaving 45 enrollees (23
and 22 from Amana and Mwanayamala District Hospitals,
respectively). Baseline characteristics comparing the two groups
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are shown in Table 1. There were no significant differences
between the two groups in age, sex, weight, parasitemia on blood
smear, blood glucose, or plasma bicarbonate. Children with
cerebral malaria had a significantly higher respiratory rate and
plasma creatinine and a longer duration of illness at the time of
enrollment. Children with cerebral malaria also had significantly
lower axillary temperature and hemoglobin concentration. As per
exclusion criteria, no children had concomitant bacteremia or
meningitis.
The median concentration of plasma PfHRP-2 in cerebral
malaria was significantly higher than in uncomplicated malaria
(1008 ng/mL [IQR 342–2572 ng/mL] and 443 ng/mL [IQR
36–1426 ng/mL], respectively, p = 0.02) (Figure 1). One patient in
each group had undetectable levels of PfHRP-2. In those with
cerebral malaria, six patients (13%) were outliers, having PfHRP-2
concentrations at least an order of magnitude lower than the rest
of the cohort (Figure 1). There was no significant difference in
mean age of the six cerebral malaria outliers (55 months [95% CI
44.1–66.9]) with the mean age in the rest of the cerebral malaria
cohort (50 months [95% CI 44.6–55.4]; p = 0.49).
On univariate analysis, natural log plasma PfHRP-2 concen-
tration correlated with lower Blantyre Coma Score (r =20.44;
p = 0.003) and with hemoglobin concentration (r =20.47;
p,0.0001), but not with plasma creatinine (r = 0.09, p = 0.54).
Natural log plasma PfHRP-2 concentration correlated with the
natural log peripheral parasitemia in uncomplicated malaria
(r = 0.41, p= 0.001), but did not correlate with natural log
peripheral parasitemia in cerebral malaria (r =20.09, p= 0.54)
or in an aggregate analysis of all patients enrolled (r = 0.16,
p = 0.11) (Figure 2).
Seven children died, all of whom had cerebral malaria. Median
plasma PfHRP-2 concentrations in those with fatal outcomes
(4000 ng/mL [IQR 1194.5–5287.3 ng/mL]) were higher than in
those who survived (926.1 ng/mL [IQR 330.7–2028.3]) (Wil-
coxon rank-sum, Holm’s Step Down Procedure, p = 0.034). A
comparison of plasma PfHRP-2 values between uncomplicated
malaria cases, cerebral malaria survivors, cerebral malaria fatal
cases found a significant difference among the three groups
(Kruskal-Wallis, p = 0.02). In patients with cerebral malaria,
increased natural log plasma PfHRP-2 was associated with an
increased risk of death on univariate analysis (OR 3.0 [95% CI
1.03–8.76]; p = 0.04). Coma score and plasma bicarbonate were
not significantly associated with death. In multivariate models
natural log PfHRP-2 remained significantly associated with death
(p = 0.04) while natural log peripheral parasitemia and plasma
bicarbonate did not (p = 0.13 and p= 0.18, respectively).
Discussion
Plasma concentration of PfHRP-2, a measure of total parasite
biomass, was associated with malaria severity, depth of coma and
mortality in Tanzanian children living in an area with mesoen-
demic malaria transmission. This supports similar findings in
adults from areas of relatively unstable transmission in Asia and
Indonesian Papua [4,6]; however it is particularly significant
because it extends the association between parasite biomass and
disease severity to African children, the demographic sub-group
with the greatest burden of severe malaria morbidity and mortality
Table 1. Baseline characteristics of children with uncomplicated malaria and cerebral malaria.
Characteristic Uncomplicated Malaria (n =61) Cerebral Malaria (n=45) P-value
Age, months 44 (38–49) 51 (46–56) 0.06
Male sex, no. (%) 30 (53.6) 15 (34.9) 0.07
Illness Duration at Enrollment, days 2.42 (1.98–2.86) 3.14 (2.64–3.64) 0.03
Weight, kg 14.2 (13–15.2) 15.4 (14.2–16.5) 0.12
Axillary temperature, uC 39.1 (38.8–39.3) 38.3 (38–38.6) ,0.001
Respiratory rate 37 (35–40) 42 (38–46) 0.03
P. falciparum peripheral parasitemia,
parasite/mL; median (inter-quartile range)
94,451 (32,440–211,265) 41,782 (7126–128,230) 0.06
Hemoglobin, g/dL 8.4 (7.8–9.1) 7.1 (6.6–7.7) 0.004
Blood glucose, mg/dL 119 (96–143) 120 (106–135) 0.92
Plasma bicarbonate, mmol/L 19.4 (16–22.7) 20.5 (19.3–21.7) 0.46
Plasma creatinine, mg/dL 0.3 (0.3–0.4) 0.7 (0.5–0.8) 0.001
doi:10.1371/journal.pone.0035985.t001
Figure 1. Plasma P. falciparum histidine-rich protein-2 concen-
tration in children with uncomplicated and cerebral malaria.
Dot plots showing plasma PfHRP-2 concentration value; box plots
showing median, interquartile range, maximum and minimum for
plasma PfHRP-2 in uncomplicated malaria (UM) and cerebral malaria
(CM). Open circles = recovery, closed circles = death.
doi:10.1371/journal.pone.0035985.g001
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[9]. PfHRP-2 levels did not correlate with parasitemia based on
peripheral blood microscopy in children with cerebral malaria.
These findings support the assertion that PfHRP-2 is more
accurate than peripheral blood smear in measuring the total body
parasite biomass in both children and adults. While we found
a significant difference in median values between cerebral malaria
and uncomplicated malaria, and an association with depth of
coma and mortality in cerebral malaria, quantitative plasma
PfHRP-2 did not clinically discriminate between cerebral malaria
and uncomplicated malaria, as the range of values in the two
groups overlapped. Nonetheless, in a population of subjects with
malaria, quantitative PfHRP-2 gives clinical researchers a measure
that controls for and/or compares parasite biomass in pathophys-
iologic studies of biomarkers or mediators of severe malaria. In
addition to this utility in clinical research, our finding that PfHRP-
2 was predictive of mortality suggests that quantitative PfHRP-2
may have prognostic value in children presenting with cerebral
malaria.
Two previous studies have measured plasma PfHRP-2 in
children with severe malaria. A small Kenyan study did not relate
PfHRP-2 with disease severity or outcome [12]. A recent study
from Papua New Guinea found no correlation between PfHRP-2
and severity of malaria infection among children with severe
malaria in a relatively high transmission area [7]. The reasons for
the lack of association in this study are not clear. The Papua New
Guinea study had an unusually low case fatality rate among
patients enrolled with severe malaria (,0.5%), suggesting less
severe disease, and used recombinant PfHRP-2 was used for
ELISA quantitation rather than the purified PfHRP-2 used in all
three studies showing associations with disease severity and
mortality [current study,4, 6]. In contrast to the Papua New
Guinea study, we (and the adult studies) found no association
between plasma PfHRP-2 and creatinine to suggest slower renal
clearance in children. Geographic variation in parasite PfHRP-2
polymorphisms may contribute [13], although plasma PfHRP-2
has been associated with disease severity and mortality elsewhere
on the island of New Guinea [6]. It is also possible that differences
in comorbidities or malaria transmission may contribute. With
relatively high rates of asymptomatic parasitemia in coastal Papua
New Guinea, low plasma PfHRP-2 levels in children clinically
diagnosed with severe malaria could occur with non-malarial
causes of severe illness associated with incidental parasitemia.
Nevertheless, we found that plasma PfHRP-2 is associated with
pediatric malaria severity and mortality in a mesoendemic trans-
mission area of Africa.
Strengths of our study include rigorous exclusion of bacteremia
and meningitis that may mimic severe malaria. A limitation lies in
the reliability of the WHO clinical case definition for cerebral
malaria. An autopsy study (without blood culture exclusion of
bacteremia) found that the clinical definition has a specificity of
only 77% [14]. Among children in our study with clinically
defined cerebral malaria and exclusion of bacteremia, there were
six low outliers (13%) who had plasma PfHRP-2 levels at least an
order of magnitude below the rest of the cerebral malaria group.
We speculate that the low PfHRP-2 values in these children could
reflect coma from another source with coincidental P. falciparum
parasitemia, higher levels of host neutralizing antibody to PfHRP-
2, or a dysregulated host inflammatory response despite low
burden of infection. Another limitation of our study is the
relatively small sample size, which could lead to a type I error (i.e.
rejecting the null hypothesis when in fact the null hypothesis is
true).
We conclude that plasma PfHRP-2 is associated with malaria
severity and mortality in Tanzanian children from a mesoendemic
area of transmission. Although further studies are needed in other
areas of Africa with higher malaria transmission and in children
with different clinical manifestations of severe malaria, our
findings support the utility of plasma PfHRP-2 in clinical research
to estimate the total parasite biomass in falciparum malaria, in
children as well as adults.
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